Darden shares lower following Q1 earnings results Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Eli Lilly (LLY) up 2% after announcing the FDA has granted approval to Retevmo for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options
UP AFTER EARNINGS -
- H.B. Fuller (FUL) up 2%
- Trip.com Group (TCOM) up 3%
- Lennar (LEN) up 1%
DOWN AFTER EARNINGS -
- Steelcase (SCS) down 5%
- Darden (DRI) down 3%
- FactSet (FDS) down 1%
- Palatin (PTN) down 5%
- KB Home (KBH) down 2%
LOWER -
- Novavax (NVAX) down 6% after JPMorgan analyst Eric Joseph downgraded the stock to Underweight from Neutral with a price target of $27, down from $132
Symbols:
FUL LLY TCOM LEN SCS DRI FDS - $430.73 /
-10.99 (-2.49%)
PTN KBH NVAX Keywords: Fly Intel, Wall Street, Top Stories, Stocks